Journal article

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

Meredith M Regan, Prudence A Francis, Olivia Pagani, Gini F Fleming, Barbara A Walley, Giuseppe Viale, Marco Colleoni, Istvan Lang, Henry L Gomez, Carlo Tondini, Graziella Pinotti, Karen N Price, Alan S Coates, Aron Goldhirsch, Richard D Gelber

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2016

Abstract

PURPOSE: Risk of recurrence is the primary consideration in breast cancer adjuvant therapy recommendations. The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breast cancer, testing exemestane plus ovarian function suppression (OFS), tamoxifen plus OFS, and tamoxifen alone. We examined absolute treatment effect across a continuum of recurrence risk to individualize endocrine therapy decision making for premenopausal women with human epidermal growth factor receptor 2 (HER2) -negative disease. PATIENTS AND METHODS: The TEXT and SOFT hormone receptor-p..

View full abstract